Physician profile
Vincent Law
NPI 1700952751
$7,675.39
in general payments reported to CMS, 2019-2025
50 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $666 · 2021: $1,328 · 2022: $749 · 2023: $1,273 · 2024: $1,492 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,027.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $993.02 | 2023-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $821.85 | 2019-2022 | |
| Novo Nordisk INC | $768.64 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $604.90 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $474.91 | 2019-2025 | Otezla, Repatha, Prolia |
| Pfizer INC. | $306.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $302.08 | 2019-2025 | |
| Abbvie INC. | $280.18 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $255.28 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $234.33 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.61 | 2020-2025 | Xifaxan |
| Lilly USA, LLC | $185.90 | 2019-2024 | Mounjaro |
| Mylan Specialty L.P. | $182.16 | 2019-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.51 | 2024-2025 | Caplyta |
| Alpha Cognition USA, INC. | $145.93 | 2025 | Zunveyl |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $126.34 | 2022-2025 | Nuplazid |
| Sanofi-Aventis U.S. LLC | $116.47 | 2019-2022 | |
| Allergan, INC. | $101.09 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $94.45 | 2020-2025 | Eliquis |
| Exact Sciences Corporation | $93.13 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $88.59 | 2024-2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $80.25 | 2023-2025 | Ztlido |
| Esperion Therapeutics, INC. | $76.37 | 2021-2025 | Nexletol |
| Axsome Therapeutics, INC. | $67.74 | 2024-2025 | Auvelity |
| Abbott Laboratories | $65.13 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Eisai INC. | $59.20 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $56.51 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $55.51 | 2022-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.15 | 2019-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $52.77 | 2020-2025 | Austedo Xr, Austedo Xr |
| Merck Sharp & Dohme LLC | $50.77 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $42.43 | 2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $41.77 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $41.19 | 2019 | |
| Ironshore Pharmaceuticals INC. | $33.81 | 2023-2024 | Jornay Pm |
| Paratek Pharmaceuticals, INC. | $32.74 | 2023-2024 | Nuzyra |
| Dexcom, INC. | $29.58 | 2021 | |
| Inogen, INC. | $28.05 | 2022 | |
| Idorsia Pharmaceuticals US INC | $27.34 | 2024 | Quviviq |
| Averitas Pharma INC. | $24.21 | 2024 | Qutenza |
| Csl Behring | $23.92 | 2019 | |
| Viatris Specialty LLC | $21.42 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $21.20 | 2023 | Gemtesa |
| Corcept Therapeutics | $20.49 | 2023 | Korlym |
| Noven Therapeutics, LLC | $20.42 | 2024 | Secuado, Xelstrym |
| Ardelyx, INC. | $19.63 | 2025 | Ibsrela |
| Collegium Pharmaceutical, INC. | $19.44 | 2025 | Jornay Pm |
| Boston Scientific Corporation | $15.74 | 2019 | |
| Amarin Pharma, INC. | $14.89 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.